Asymmetric Dearomatization of Phthalazines by Anion-Binding Catalysis.
A straightforward methodology for the enantioselective synthesis of 1,2-dihydrophthalazines...
Phtalazines : Questions médicales fréquentes
Questions fréquentes et termes MeSH associés
Diagnostic 5
#1
Comment diagnostiquer une intoxication aux phtalazines ?
Le diagnostic repose sur l'historique médical et des tests sanguins pour détecter les niveaux de phtalazines.
#2
Quels tests sont utilisés pour évaluer l'effet des phtalazines ?
Des tests de fonction hépatique et des analyses de sang peuvent être effectués pour évaluer l'effet des phtalazines.
#3
Quels symptômes indiquent un surdosage de phtalazines ?
Les symptômes incluent des nausées, des vertiges, et des troubles neurologiques.
#4
Comment évaluer l'efficacité des phtalazines en traitement ?
L'efficacité est évaluée par l'amélioration des symptômes cliniques et des résultats de tests.
#5
Quels examens complémentaires sont nécessaires ?
Des examens d'imagerie et des tests de laboratoire peuvent être nécessaires pour un diagnostic complet.
Symptômes 5
#1
Quels sont les effets secondaires courants des phtalazines ?
Les effets secondaires incluent des maux de tête, des nausées et des éruptions cutanées.
#2
Les phtalazines provoquent-elles des réactions allergiques ?
Oui, des réactions allergiques peuvent survenir, notamment des démangeaisons et des éruptions.
#3
Quels symptômes indiquent une hypersensibilité aux phtalazines ?
Des symptômes comme des éruptions cutanées, des démangeaisons et un gonflement peuvent indiquer une hypersensibilité.
#4
Les phtalazines affectent-elles le système nerveux ?
Oui, elles peuvent provoquer des vertiges, des maux de tête et des troubles de la coordination.
#5
Quels signes d'intoxication aux phtalazines ?
Les signes incluent confusion, somnolence, et troubles de la vision.
Prévention 5
#1
Comment prévenir les effets secondaires des phtalazines ?
Pour prévenir les effets secondaires, suivez les instructions du médecin et signalez tout symptôme.
#2
Y a-t-il des précautions à prendre avec les phtalazines ?
Oui, il est important d'informer le médecin de toutes les allergies et médicaments en cours.
#3
Les femmes enceintes peuvent-elles prendre des phtalazines ?
Les femmes enceintes doivent consulter leur médecin avant de prendre des phtalazines en raison des risques potentiels.
#4
Comment éviter les interactions médicamenteuses avec les phtalazines ?
Informez toujours votre médecin de tous les médicaments que vous prenez pour éviter les interactions.
#5
Quelles sont les recommandations pour un usage sûr des phtalazines ?
Respectez la posologie prescrite et assistez aux rendez-vous de suivi pour un usage sûr.
Traitements 5
#1
Comment traiter une intoxication aux phtalazines ?
Le traitement inclut l'arrêt du médicament et des soins symptomatiques, comme l'hydratation.
#2
Les phtalazines sont-elles utilisées pour traiter l'hypertension ?
Oui, certaines phtalazines sont prescrites pour traiter l'hypertension et d'autres troubles cardiovasculaires.
#3
Quels médicaments interagissent avec les phtalazines ?
Les anticoagulants et certains antibiotiques peuvent interagir avec les phtalazines.
#4
Comment surveiller le traitement par phtalazines ?
La surveillance inclut des contrôles réguliers de la pression artérielle et des tests sanguins.
#5
Les phtalazines nécessitent-elles une prescription médicale ?
Oui, les phtalazines doivent être prescrites par un professionnel de santé qualifié.
Complications 5
#1
Quelles complications peuvent survenir avec les phtalazines ?
Les complications incluent des troubles hématologiques et des réactions cutanées sévères.
#2
Les phtalazines peuvent-elles causer des problèmes cardiaques ?
Oui, des effets indésirables cardiaques peuvent survenir, nécessitant une surveillance étroite.
#3
Comment gérer les complications liées aux phtalazines ?
La gestion des complications nécessite souvent l'arrêt du médicament et un traitement symptomatique.
#4
Les phtalazines peuvent-elles affecter le foie ?
Oui, elles peuvent provoquer des anomalies hépatiques, nécessitant un suivi régulier des tests hépatiques.
#5
Quels sont les risques à long terme des phtalazines ?
Les risques à long terme incluent des troubles chroniques et des effets indésirables persistants.
Facteurs de risque 5
#1
Quels facteurs augmentent le risque d'effets indésirables des phtalazines ?
Les antécédents d'allergies et l'utilisation concomitante d'autres médicaments augmentent le risque.
#2
Les personnes âgées sont-elles plus à risque avec les phtalazines ?
Oui, les personnes âgées peuvent être plus sensibles aux effets secondaires des phtalazines.
#3
Y a-t-il des prédispositions génétiques aux effets des phtalazines ?
Certaines prédispositions génétiques peuvent influencer la réponse aux phtalazines.
#4
Les antécédents médicaux influencent-ils l'utilisation des phtalazines ?
Oui, des antécédents de maladies hépatiques ou cardiaques peuvent influencer leur utilisation.
#5
Quels comportements augmentent le risque d'effets indésirables ?
La consommation d'alcool et l'automédication peuvent augmenter le risque d'effets indésirables.
Contenu validé par Dr Olivier Menir
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 27/03/2026
Contenu vérifié selon les dernières recommandations médicales
Sous-catégories
3 au totalAuteurs principaux
Khaled El-Adl
5 publications dans cette catégorie
Affiliations :
- Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Heliopolis University for Sustainable Development, El Salam City, Cairo, Egypt.
Publications dans "Phtalazines" :
-
Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors.
Archiv der Pharmazie 2021-10-01
-
Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants.
Archiv der Pharmazie 2019-04-15
-
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Archiv der Pharmazie 2021-08-19
-
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation.
RSC advances 2024-07-08
-
Phthalazine-1,4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking.
Molecular diversity 2018-08-30
Ibrahim H Eissa
4 publications dans cette catégorie
Affiliations :
- Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
Publications dans "Phtalazines" :
-
Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors.
Archiv der Pharmazie 2021-10-01
-
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Archiv der Pharmazie 2021-08-19
-
Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
Journal of enzyme inhibition and medicinal chemistry
-
Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Bioorganic chemistry 2020-08-26
Fathalla Khedr
3 publications dans cette catégorie
Affiliations :
- Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
Publications dans "Phtalazines" :
-
Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors.
Archiv der Pharmazie 2021-10-01
-
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Archiv der Pharmazie 2021-08-19
-
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation.
RSC advances 2024-07-08
Hamada S Abulkhair
3 publications dans cette catégorie
Affiliations :
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
Publications dans "Phtalazines" :
-
Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors.
Archiv der Pharmazie 2021-10-01
-
Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants.
Archiv der Pharmazie 2019-04-15
-
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Archiv der Pharmazie 2021-08-19
Abdel-Ghany A El-Helby
3 publications dans cette catégorie
Affiliations :
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Publications dans "Phtalazines" :
-
Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants.
Archiv der Pharmazie 2019-04-15
-
Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Bioorganic chemistry 2020-08-26
-
Phthalazine-1,4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking.
Molecular diversity 2018-08-30
Mohamed S Nafie
3 publications dans cette catégorie
Affiliations :
- Chemistry Department, Faculty of Science, Suez Canal University P.O. 41522 Ismailia Egypt mohamed_nafie@science.suez.edu.eg samir_elrayes@science.suez.edu.eg.
- Department of Chemistry, College of Sciences, University of Sharjah P.O. 27272 Sharjah United Arab Emirates mohamed.elsayed@sharjah.ac.ae.
Publications dans "Phtalazines" :
-
Synthesis of novel phthalazine-based derivatives with potent cytotoxicity against HCT-116 cells through apoptosis and VEGFR2 inhibition.
RSC advances 2024-04-24
-
Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
Journal of enzyme inhibition and medicinal chemistry
-
Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies.
BMC chemistry 2023-07-27
Cüneyt Türkeş
2 publications dans cette catégorie
Affiliations :
- Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Turkey.
Publications dans "Phtalazines" :
-
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors.
Journal of molecular recognition : JMR 2022-09-26
-
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Bioorganic chemistry 2019-05-21
Mustafa Arslan
2 publications dans cette catégorie
Affiliations :
- Department of Chemistry, Faculty of Arts and Sciences, Sakarya University, Sakarya, Turkey.
Publications dans "Phtalazines" :
-
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors.
Journal of molecular recognition : JMR 2022-09-26
-
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Bioorganic chemistry 2019-05-21
Yeliz Demir
2 publications dans cette catégorie
Affiliations :
- Department of Pharmacy Services, Nihat Delibalta Göle Vocational High School, Ardahan University, Ardahan, Turkey.
Publications dans "Phtalazines" :
-
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors.
Journal of molecular recognition : JMR 2022-09-26
-
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Bioorganic chemistry 2019-05-21
Liridon Çoçaj
2 publications dans cette catégorie
Affiliations :
- Department of Chemistry, Faculty of Mathematical and Natural Sciences, Prishtina University, Republic of Kosova, Serbia.
Publications dans "Phtalazines" :
-
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors.
Journal of molecular recognition : JMR 2022-09-26
-
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Bioorganic chemistry 2019-05-21
Arleta Rifati Nixha
2 publications dans cette catégorie
Affiliations :
- Department of Chemistry, Faculty of Mathematical and Natural Sciences, Prishtina University, Republic of Kosova, Serbia.
Publications dans "Phtalazines" :
-
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors.
Journal of molecular recognition : JMR 2022-09-26
-
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Bioorganic chemistry 2019-05-21
Şükrü Beydemir
2 publications dans cette catégorie
Affiliations :
- Department of Biochemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
- The Rectorate of Bilecik Şeyh Edebali University, Bilecik, Turkey.
Publications dans "Phtalazines" :
-
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors.
Journal of molecular recognition : JMR 2022-09-26
-
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Bioorganic chemistry 2019-05-21
Carmen Terán
2 publications dans cette catégorie
Affiliations :
- Departamento de Química Orgánica and Instituto de Investigación Sanitaria Galicia Sur (IISGS), Universidade de Vigo, 36310, Vigo, Spain. Electronic address: mcteran@uvigo.es.
Publications dans "Phtalazines" :
-
Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry.
European journal of medicinal chemistry 2018-10-25
-
Novel Phthalazin-1(2H)-One Derivatives Displaying a Dithiocarbamate Moiety as Potential Anticancer Agents.
Molecules (Basel, Switzerland) 2022-11-22
Pedro Besada
2 publications dans cette catégorie
Affiliations :
- Departamento de Química Orgánica and Instituto de Investigación Sanitaria Galicia Sur (IISGS), Universidade de Vigo, 36310, Vigo, Spain.
Publications dans "Phtalazines" :
-
Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry.
European journal of medicinal chemistry 2018-10-25
-
Novel Phthalazin-1(2H)-One Derivatives Displaying a Dithiocarbamate Moiety as Potential Anticancer Agents.
Molecules (Basel, Switzerland) 2022-11-22
Noemí Vila
2 publications dans cette catégorie
Affiliations :
- Departamento de Química Orgánica and Instituto de Investigación Sanitaria Galicia Sur (IISGS), Universidade de Vigo, 36310, Vigo, Spain.
Publications dans "Phtalazines" :
-
Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry.
European journal of medicinal chemistry 2018-10-25
-
Novel Phthalazin-1(2H)-One Derivatives Displaying a Dithiocarbamate Moiety as Potential Anticancer Agents.
Molecules (Basel, Switzerland) 2022-11-22
Rezk R A Ayyad
2 publications dans cette catégorie
Affiliations :
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Publications dans "Phtalazines" :
-
Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants.
Archiv der Pharmazie 2019-04-15
-
Phthalazine-1,4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking.
Molecular diversity 2018-08-30
Hazem Elkady
2 publications dans cette catégorie
Affiliations :
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Publications dans "Phtalazines" :
-
Design, synthesis, in silico ADMET profile and GABA-A docking of novel phthalazines as potent anticonvulsants.
Archiv der Pharmazie 2019-04-15
-
Phthalazine-1,4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking.
Molecular diversity 2018-08-30
Angel H Romero
2 publications dans cette catégorie
Affiliations :
- Cátedra de Química General, Facultad de Farmacia, Universidad Central de Venezuela, Caracas, Venezuela.
- Laboratorio de Ingeniería Genética, Instituto de Biomedicina, Hospital Vargas, Caracas, Venezuela.
- Laboratorio de Química Medicinal y Heterociclos, Departamento de Química, Universidad Simón Bolívar, Sartenejas, Baruta, Venezuela.
Publications dans "Phtalazines" :
-
Antileismanial activity, mechanism of action study and molecular docking of 1,4-bis(substituted benzalhydrazino)phthalazines.
Archiv der Pharmazie 2019-04-23
-
Anticancer potential of new 3-nitroaryl-6-(N-methyl)piperazin-1,2,4-triazolo[3,4-a]phthalazines targeting voltage-gated K
Bioorganic chemistry 2020-06-19
Mohamed-Kamal Ibrahim
2 publications dans cette catégorie
Affiliations :
- Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt.
Publications dans "Phtalazines" :
-
Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Archiv der Pharmazie 2021-08-19
-
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation.
RSC advances 2024-07-08
Tamer M Ibrahim
2 publications dans cette catégorie
Affiliations :
- d Pharmaceutical Chemistry Department, Faculty of Pharmacy , Kafrelsheikh University , Kafr El-Sheikh , Egypt.
Publications dans "Phtalazines" :
-
Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition.
Journal of enzyme inhibition and medicinal chemistry
-
Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer.
European journal of medicinal chemistry 2022-08-31
Sources (51 au total)
Atroposelective Ir-Catalyzed C-H Borylation of Phthalazine Heterobiaryls.
The atroposelective iridium-catalyzed borylation of menthyloxy-substituted phthalazine heterobiaryls with diborons is reported. Utilizing [Ir(OMe)(COD)]...
Phthalazine sulfonamide derivatives as carbonic anhydrase inhibitors. Synthesis, biological and in silico evaluation.
Carbonic Anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide involved in several biological processes. They show a wide diversity in tis...
Phthalazine as a Diene in Diels - Alder Reactions with P- and As-Containing Anionic Dienophiles: Comparison of Possible Reaction Channels.
Phthalazine behaves as a diene in Diels-Alder (DA) cycloadditions, typically at the pyridazine ring, however, its application is limited because these reactions usually require harsh conditions or sop...
PARP inhibitors in prostate cancer: clinical applications.
Despite recent advancements in the treatment of metastatic castrate-resistant prostate cancer (mCRPC), this disease remains lethal. A novel family of targeted pharmaceuticals known as poly-ADP-ribose ...
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis.
Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib and niraparib have shown promise in extending progression-free survival (PFS) in patients with platinum-sensitive recurrent (PSR) epithe... 82 patients diagnosed with PSR epithelial ovarian, tubal, or primary peritoneal cancer between May 2017 and September 2023 were initially enrolled from our hospital. However, 16 patients had prior exp... Among the 55 patients with PSR epithelial ovarian cancer, 18 received olaparib as maintenance therapy, 19 received niraparib, and 18 opted for observation. PARP inhibitor therapy significantly extende... Our retrospective study demonstrates that PARP inhibitor maintenance therapy, including olaparib and niraparib, significantly prolongs PFS in patients with PSR epithelial ovarian, tubal, or primary pe...
Radiosensitizing Effect of PARP Inhibition on Chondrosarcoma and Chondrocyte Cells Is Dependent on Radiation LET.
Chondrosarcoma is a rare malignant tumor that forms in bone and cartilage. The primary treatment involves surgical removal of the tumor with a margin of healthy tissue. Especially if complete surgical...
The TALAPRO-3 study design: a plain language summary.
This summary is about the ongoing research study called TALAPRO-3. This study is testing the use of two medicines called talazoparib and enzalutamide. The two medicines are being used together as a tr... Metastatic castration-sensitive prostate cancer is known as mCSPC for short. It is cancer that has started in the prostate and spread to other body parts. The prostate is a gland below the bladder and... In this study, some patients will take talazoparib plus enzalutamide while others will take a placebo plus enzalutamide. Talazoparib and enzalutamide are two different cancer medicines. Talazoparib is... This study aims to find out if treatment with talazoparib plus enzalutamide increases the length of time the patients in the study live without their cancer getting worse, or them dying, compared with...
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HR... We conducted a systematic review of trials regarding PARPi- based therapies on mCRPC in 2nd -line setting and performed a Bayesian network meta-analysis (NMA). Radiographic progression-free survival (... Four RCTs comprised of 1024 patients (763 harbored homologous recombination repair (HRR) mutations) were identified for quantitative analysis. Regarding rPFS, olaparib monotherapy, rucaparib and cedir... PARPi-based therapy showed considerable efficacy for mCRPC patients with HRD in 2nd -line setting. However, patients should be treated accordingly based on their genetic background as well as the effi... CRD42023454079....
Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer.
Poly (ADP-ribose) polymerase inhibitors have been increasingly used in ovarian cancer treatment. However, the real-world safety data of these drugs in Japanese patients are limited. This retrospective...